Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor" [Biochem. Biophys. Rep. 21 (2020) 100726].
Hara T, Kimura A, Miyazaki T, Tanaka H, Morimoto M, Nakai K, Soeda J. Hara T, et al. Among authors: kimura a. Biochem Biophys Rep. 2020 Aug 20;24:100797. doi: 10.1016/j.bbrep.2020.100797. eCollection 2020 Dec. Biochem Biophys Rep. 2020. PMID: 33381660 Free PMC article.
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Nakayama Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A, Tamada S. Tomita Y, et al. Among authors: kimura a. Int J Urol. 2020 Nov;27(11):952-959. doi: 10.1111/iju.14329. Epub 2020 Aug 12. Int J Urol. 2020. PMID: 32789967 Free PMC article. Clinical Trial.
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Nakaigawa N, Tomita Y, Tamada S, Tatsugami K, Osawa T, Oya M, Kanayama H, Miura Y, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Kimura A. Nakaigawa N, et al. Among authors: kimura a. Int J Clin Oncol. 2023 Mar;28(3):416-426. doi: 10.1007/s10147-022-02283-w. Epub 2023 Jan 3. Int J Clin Oncol. 2023. PMID: 36595123 Free PMC article. Clinical Trial.
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. Agarwal N, et al. Among authors: kimura a. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17. Future Oncol. 2022. PMID: 35034502
Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model.
Yakubo S, Abe H, Li Y, Kudo M, Kimura A, Wakabayashi T, Watanabe Y, Kimura N, Setsu T, Yokoo T, Sakamaki A, Kamimura H, Tsuchiya A, Kamimura K, Terai S. Yakubo S, et al. Among authors: kimura a. Diseases. 2024 Dec 4;12(12):317. doi: 10.3390/diseases12120317. Diseases. 2024. PMID: 39727647
A case of cerebral amyloid angiopathy with ipsilateral tau and contralateral amyloid PET uptake related to cadaveric dura mater implanted in childhood.
Hatakeyama Y, Kimura AM, Tsuboguchi S, Ratanov M, Nakamura K, Hatakeyama M, Nakamura Y, Watanabe M, Murakami Y, Saito Y, Murayama S, Kasuga K, Ikeuchi T, Igarashi H, Onodera O, Shimada H. Hatakeyama Y, et al. Among authors: kimura am. Eur J Nucl Med Mol Imaging. 2024 Dec 19. doi: 10.1007/s00259-024-07030-z. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39699685 No abstract available.
3,235 results